Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi’s risk assessment program and access to breast specialists with Myriad’s MyRisk® with RiskScore® Hereditary Cancer Test. “After losing my mom ...